Comments
Glenmark Pharmaceuticals Ltd. secured final approval from the United States Food & Drug Administration (FDA) for its Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%. The company informed that the solution was deemed bioequivalent and therapeutically equivalent to Combigan Ophthalmic Solution, 0.2%|0.5%, produced by AbbVie, Inc. Glenmark Pharmaceuticals Inc., USA will distribute the product in the US.
According to IQVIA sales data for the 12-month period ending March 2024, the market for Combigan Ophthalmic Solution, 0.2%|0.5%, reached annual sales of approximately $290 million.
Glenmark’s current US portfolio includes 196 products authorised for distribution and 51 Abbreviated New Drug Applications (ANDAs) awaiting approval from the FDA. The company informed they are actively seeking external development partnerships to expand its existing pipeline and portfolio.
The shares were up by 1.02% to ₹1016.45 at 11 am on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.